• Explore /
  • Poster
  • / A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).

A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Michael Cecchini

Yale University, New Haven, CT

Michael Cecchini , Jeremy S. Kortmansky , Jill Lacy , Neal A. Fischbach , Jaykumar Ranchodbhai Thumar , Kert D. Sabbath , Christina M. Gomez , Jonathan Sporn , Stacey Stein , Howard S. Hochster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02848079

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 630)

DOI

10.1200/JCO.2019.37.4_suppl.630

Abstract #

630

Poster Bd #

K15

Abstract Disclosures

Similar Posters

First Author: Nicolas Huyghe

First Author: Jiwon Lee

First Author: Hideaki Bando

First Author: Akihito Tsuji